- Titre
- Phase II study of melphalan as a single-agent infused over a 24-hour period with individual adapted dosing in patients with recurrent epithelial ovarian cancer
- Créateurs - sans rôle
- Philippe Mougenot - Oncopharmacology Department, Pharmacy Service, University Montpellier I, Montpellier, FranceMichel Fabbro - Department of Medicine, Val d'Aurelle Anticancer Centre, parc Euromedecine, University Montpellier I, Montpellier, FranceFrancoise Bressolle - Oncopharmacology Department, Pharmacy Service, University Montpellier I, Montpellier, FranceDamien Pouessel - Department of Medicine, Val d'Aurelle Anticancer Centre, parc Euromedecine, University Montpellier I, Montpellier, FranceStephane Culine - Department of Medicine, Val d'Aurelle Anticancer Centre, parc Euromedecine, University Montpellier I, Montpellier, FranceFrederic Pinguet - Oncopharmacology Department, Pharmacy Service, University Montpellier I, Montpellier, France
- Détails de publication
- Oncology reports, Vol.15(1), pp.237-241
- Éditeur
- S.n.
- Nombre de pages
- 5
- Identifiants
- 99162656909311
- Unité académique
- Institut de Recherche en Cancérologie de Montpellier - IRCM
- Langue
- English
- Type de ressource
- Journal article
Article de revue
Phase II study of melphalan as a single-agent infused over a 24-hour period with individual adapted dosing in patients with recurrent epithelial ovarian cancer
Oncology reports, Vol.15(1), pp.237-241
2006
PMID: 16328062
Indicateurs
1 Consultations de la notice